Objectives: The management of concomitant intra-abdominal malignancy (IAM) and abdominal aortic 45 aneurysm (AAA) remains a challenge, even though malignancy is common in this elderly population. 46
What this study adds to the existing literature and how it will influence future clinical practice 22
The aim of this study was to determine outcomes in patients undergoing abdominal aortic aneurysm 23 (AAA) repair [endovascular (EVAR) or open] who have a synchronous malignancy. Synchronous intra-24 abdominal cancer is relatively common in patients undergoing AAA-repair and surgeons are faced with 25
the dilemmas of what type of repair to offer and in what sequence. Our findings support that EVAR is 26 superior regarding short-term mortality. Both EVAR and OAR were associated with significant short-27 term morbidity, which merits careful planning and close follow-up in this patient group. Future studies 28 should look into the optimal timing of AAA-repair, for which limited data exist. The management of concomitant abdominal aortic aneurysms (AAA) and intra-abdominal malignancy 65 (IAM) is challenging. The introduction of endovascular AAA repair (EVAR), which has favourable 66 early and medium-term outcomes(1, 2), has further complicated decision-making in this context. 67
Certain patients may not require surgical resection, but in those that do, the dilemma is whether to treat 68 the AAA first, which risks delaying the treatment of the cancer, or to treat the cancer first with the 69 potential risk of AAA-rupture and death. A third option is to treat both pathologies simultaneously, 70 especially if the patient is fit enough to undergo a prolonged procedure. However, simultaneous AAA 71 and cancer procedures may be associated with increased risk of graft infection, especially within the 72 context of synchronous gastrointestinal surgery and open aneurysm repair (OAR). Furthermore, cancer 73 resection is fraught with an increased risk of bleeding as anticoagulation is necessary for aneurysm 74 surgery (OAR or EVAR). This increased risk of bleeding may be offset by an increased hypercoagulable 75 state often associated with malignancy (3), however this may compromise the subsequent post-76 operative graft patency and peripheral thrombo-embolic complications following OAR or EVAR. Thus 77 the clinical problem is complex. 78
Randomised-trials have shown short-term superiority of EVAR over OAR (1, 2, 4) and the majority of 79 patients have anatomy suitable for EVAR (5, 6) . In the current minimally invasive era there is a need to 80 determine the effect of malignancy on outcomes following EVAR and the risks of EVAR in patients 81 with concomitant IAM. 82
Following the above, the aim of this study is to assess mortality and morbidity in patients with a 83 synchronous AAA and an IAM, through a systematic literature-review and meta-analysis. 
Search Strategy 90
The Medline (1950 to present) , EMBASE (1980 to present) , Cochrane Library and Google Scholar 91 (Timeframe = "Anytime") databases were interrogated (date of electronic search: 15 th July 2015) to 92 identify all relevant manuscripts reporting outcomes after AAA repair in patients with a concomitant 93 malignancy. The search was limited to studies in human. Various combinations of MeSH terms, phrases 94
and free text were used to ensure all relevant articles were identified. The search terms were: Cancer, 95 neoplasia, tumo(u)r, abdominal aortic aneurysm. Search terms were combined with the use of Boolean 96 operators (AND, OR, NOT). Titles and Abstracts of all publications identified through the search 97 strategy were screened by AS, OA, and RK independently and consensus regarding inclusion of each 98 manuscript in the analysis was reached following discussion with the senior authors (AS, RDS, MJB). 99
At this stage, once all relevant publications identified through the online search had been obtained, the 100 references of all manuscripts were also manually searched (by AS and RK) to identify potential 101 publications that had been missed. The Preferred Reporting Items for Systematic Reviews and Meta-102 Analyses (PRISMA) guidance was adhered to at all stages (7, 8) . Authors were contacted twice to obtain 103 missing data; manuscripts not reporting at least peri-operative mortality were not included. 104
Inclusion Criteria 105
Any papers that reported (and where data could be extracted) patient outcomes on intra-abdominal 106 visceral cancer in the context of AAA were included. 107
Exclusion Criteria 108
Articles that contained only a single case (i.e. case report) and conference proceedings were excluded. 109
The authors of papers with missing information were contacted to obtain relevant missing data and if 110 no operative outcomes could be obtained, these publications were excluded. 111
Study Selection 112
Two independent reviewers (RK, OA) selected the appropriate studies for both inclusion and exclusion 113 criteria. Discrepancy between reviewers was resolved by a third independent author, AS. No specific 114 quality criteria were applied when excluding articles, given that no prospective randomized articles 115 were identified and all relevant publications consisted of case-series, mostly of retrospective nature. 116
The Newcastle-Ottawa scale (9)was used to assess study-quality by examining patient selection 117 methods, comparability of groups and assessment of outcome. None of the series included in the 118 eventual analysis achieved a rating of more than 4 stars. 119
Definitions 120
Abdominal aortic aneurysm was defined as aortic diameter exceeding 3.0cm on cross-sectional 121
imaging. Complications and other patient and procedural characteristics were defined using the 122 reporting criteria by Ahn and Chaikof et al for OAR and EVAR (10, 11) . 123
Outcome definitions 124
The primary outcome measure was 30-day mortality. Further outcomes extracted from the articles 125 included aneurysm-related complications (graft limb occlusions, re-interventions, endoleaks and sac 126 expansions) during the peri-operative period and long-term follow-up, overall patient survival and 127 major complications; all events are reported using the aforementioned reporting criteria(10, 11). 128 129
Statistical analysis 130
Analyses were performed using the R Package for Windows (version 3.0). Continuous variables of 131 interest are reported using mean values and standard deviation (SD) or median values and range, for 132 parametric and non-parametric data respectively. Random or fixed effects meta-analysis was performed 133 using the proportions of patients who experience an event (inpatient or 30-day mortality) as outcome 134 data, as necessary, based on between-study heterogeneity. The latter was assessed using the I 2 statistic, 135 which describes the percentage of total variation across studies that arises due to heterogeneity rather 136 than chance or random error. A value greater than 50% was considered to reflect significant heterogeneity owing to real differences in study populations, protocols, interventions and outcomes for 138 the purposes of this study and hence a random effects model was used in this case. A p value level <0.05 139 was considered statistically significant. The Newcastle-Ottawa scale (9)was used to assess study 140 quality. 141
142

RESULTS 143
Search Results 144
The initial electronic search identified a total of 658 potential journal articles and after removal of 27 145 duplicates, a total of 631 unique article titles and abstracts were reviewed, as described above. From 146 this, 258 were deemed to be suitable for full-text review. Following that, we identified 36 case-series 147 case-reports reported on outcomes after EVAR on patients with lymphoma (excluded) and 1 series 150 reported on lymphoma incidence after EVAR. A further 4 case reports reporting on patients undergoing 151 EVAR with concomitant lung cancer we also excluded. All series included in the literature synthesis 152
were retrospective reports; no randomized trials or prospective cohort-studies were identified. All 153 articles included in the synthesis had a 3 or 4 star rating based on the Newcastle-Ottawa scale, hence no 154 study-quality related exclusion criteria where applied. Articles included in the analysis were published 155 between 1989 and 2015; only 1 article was published prior to the introduction of EVAR in 1991 and 5 156 prior to 2000. None of the articles described outcomes pertaining to repair of type IV, supra-renal or 157 inflammatory/mycotic aneurysms. 158
These series reported outcomes in patients undergoing operative intervention of AAA within the context 159 of IAM: 18 colorectal, 9 urological, 3 gastric and 1 pancreatic malignancy. Five series described 160 outcomes in a variety of mixed cancers. This review focuses on elective AAA repairs; overall 10 161 emergency AAA repairs were described but these were excluded from the subsequent data synthesis. 162
Four of these patients experience a rupture whilst awaiting AAA treatment after cancer surgery; no 163 rupture occurred whilst awaiting cancer surgery. 164
A total of 8 series reported solely EVAR outcomes, whilst 16 reported on OAR and the remaining 12 165 series reported on both OAR and EVAR. Tables 1, 2 and 3 describe study characteristics and reported 166 outcomes. 167
Mortality 168
The overall weighted 30-day all-cause mortality for the entire 36 series (including both EVAR and 169 OAR) was 9.6% [6.7% to 13.2%, 95% Confidence Interval (CI); I^2: 0, p=0.98]. For the studies that 170 reported mortality separately for EVAR and OAR, the overall weighted 30-day mortality for OAR was 171 11% (6.6% to 17.9%, I^2: 0, p=0.84); none of the patients in the EVAR series (7 publications reporting 172 on 37 patients) had died at 30 days (Tables 1 to 3 and Figure 2 ). For the series reporting only colorectal 173 malignancies, the cumulative mortality at 30 days was 2.4% (1.2% to 5.5%). 174
Morbidity 175 The overall 30-day major complication-rate was 17.4% (11.4% to 25.4%, I^2: 56.9%, p<0.001). Type 176 II endoleaks and events that did not require intervention or hospital admission were not considered as 177 major complications, as per Chaikof et al(10) . The equivalent overall weighted 30-day major 178 complication-rate for EVAR was 20.4% (10% to 37.4%, I^2: 0, p=0.58) and 15.4% for OAR (7% to 179 30.8%, I^2: 0, p=0.63). The proportion of patients having their cancer and AAA treated simultaneously 180 was 42% (30% to 52.3%) and non-simultaneously was 56.6% (42.1% to 70.1%). There was great 181 variability regarding the timing of treatment in the non-simultaneous groups (cancer or AAA first) 182 amongst the series (Tables 1 to 3) . As a result, given the lack of individual patient data, we could not 183 perform a meaningful analysis regarding the association between timing of repair (cancer or AAA first) 184 and subsequent outcomes. 185
Long-term Results 186
Long-term outcomes were reported in a non-uniform manner across the 36 series and none reported the 187 precise number of patients adhering to follow-up at specific time-points, prohibiting meta-analysis for 188 long-term events (mortality and morbidity). Seven case series (5 publications) reported cancer 189 recurrence data during follow-up on 31 patients who underwent EVAR. Of these 31 patients there were 190 no recurrences of cancer at the last known follow-up (mean number of months ranged from 24 to 64 191 months). Twelve individual series reported recurrence of cancer data within the context of OAR for a 192 total of 81 OAR patients. Ten of these 81 patients (12.3%) were found to have recurrence of their 193 primary cancer within the date of the last known follow up (mean number of months ranged from 17.5 194 to 73 months). Data from 11 series (9 papers) allowed identification of 'any cause' mortality rates to be 195 determined for EVAR patients (total n=65) whilst 17 OAR series were identified (total n=217 patients). 196 "Any cause mortality" was defined to have occurred outside of the peri-operative, 30 day period, as 197 these may be reasonably attributable to operative intervention(s) and/or short-term complications. In 198 the EVAR cohort 3 patients (4.6%) had died at last known follow up (mean number of months ranged 199 from 24 to 64 months). In the OAR cohort 23 (10.6%) had died at last known follow up (mean number 200 of months ranged from 4 to 73 months). 201 202
Discussion 203
In this study we aimed to apply meta-analysis to a literature review of 36 case series pertaining to 204 operative intervention in AAA within the context of concurrent intra-abdominal malignancy. We aimed 205 to assess whether OAR or EVAR was favourable within the context of intervention for cancer be it: 206 prior to, simultaneously or after surgical intervention for cancer. We looked at outcomes primarily with 207 respect to 30 day complications (mortality, morbidity) as long-term data were not uniformly reported 208 to allow meta-analysis at specific time-point. However, in the longer term, we did determine mortality 209 at last known follow up and cancer recurrence for a subset of studies with such available data. Overall, 210
this study suggests that EVAR has favourable short-term mortality rates compared to OAR in the 211 context of malignancy, but morbidity is high (compared to historical data for malignancy-free patients) 212 after both EVAR and OAR, which merits for closer follow-up. 213 The present meta-analysis is of pertinence because increasingly 'Cancer and Neoplasms' as a disease 214 entity represent the leading causes of death in England and Wales(42) . The World Health Organisation 215 forecasts deaths from cancer to continue to increase globally (WHO)(42). Arguably, therefore, a 216 concurrent malignancy in patients presenting with an AAA will be an increasingly common issue that 217 vascular surgeons will have to face in the future, especially given that minimally invasive methods now 218 allow treatment of pathologies with relative safety in older and frailer individuals. As a result, it is 219 important to be aware of which treatment strategy is optimal and associated short and long-term 220
outcomes. 221
Earlier studies investigating outcomes in patients with cancer and AAA largely focused on 222 complications following OAR and aimed to determine the best management approach for those with 223 both pathologies. Most studies advocated sequential tumour resection before or after OAR whilst a 224
minority recommended simultaneous open surgery. The latter does bear the risks of graft infection and 225 bleeding due to anticoagulation (heparin) during the AAA procedure. In the current endovascular era, 226 however, these recommendations are no longer applicable, given the minimally invasive nature of 227 EVAR (does not require a laparotomy) and the fact that modern devices and contemporary techniques 228 such as fEVAR have widened the anatomical spectrum of EVAR(43). However, conversely, the pro-229 coagulable state associated with the presence of malignancy is an important consideration and confers 230 yet another co-morbid factor that may adversely impact on limb patency and increased post-operative 231 ischaemia secondary to thrombo-embolic events, such as limb occlusion, after EVAR. 232
In one of the very few publications directly comparing EVAR and OAR in the context of malignancy, 233
Porcellini et al (38) compared the impact of treating patients with cancer and AAA with either OAR or 234 EVAR and found that EVAR was associated with a shorter length of stay, fewer post-operative 235 complications and better survival outcomes at both 1-and 2-years. As a result, they recommend that 236
EVAR followed by cancer resection should be considered as the preferred option in patients with 237 morphologically suitable aneurysms. Unfortunately, further comparative data in the literature for this 238 population are insufficient to allow meaningful meta-analysis with cumulative odds/hazard ratios to be 239 undertaken. We therefore set out to combine literature reports on EVAR and OAR separately, in patients 240 with malignancy. Morbidity rates in our meta-analysis, were relatively high following both OAR and 241 EVAR, in comparison to AAA repair per se in the absence of IAM [20.4% for EVAR at 30 days (10% 242 to 37.4%) and 15.4% for OAR at 30 days (7% to 30.8%)]. However, there were no peri-operative 243 deaths following EVAR. Interestingly, the OAR in this meta-analysis was also associated with high 244 long term 'any cause' mortality; 10.6% at last follow up compared with 4.6% in the EVAR cohort. 245
Direct comparisons at specific time-points were not possible for these long term outcomes due to lack 246 of patient specific data from the reports. 247
The most prevalent cancer types in those undergoing EVAR in the literature were colorectal and 248 urological malignancies and this is similar to the prevalence reported by Porcellini et al (38) . Most of 249 the previous studies in this area have focused on colorectal malignancies despite the fact that other 250 gastrointestinal and urological malignant resections also require intra-abdominal intervention and 251 therefore pose comparable risks in terms of post-operative AAA rupture. Therefore, our rationale was 252 to include all types of IAM in our systematic review. We are not aware of another publication 253 endeavouring to pool data for all patients with IAM and AAA. The majority of series did focus on 254 colorectal malignancy in our literature synthesis, but we identified another 17 series which reported on 255 other types of malignancy. We have not included other types of malignancy (such as lymphoma, lung 256 cancer) due to the fact that there are only scarce reports in the literature in patients with such a 257 malignancy and a synchronous AAA. Also, these do not require resection of an intra-abdominal tumour 258 in order to be treated curatively. 259
A number of biological mechanisms exist by which cancer could influence outcomes in patients with 260 AAA, which could explain the high-rate of morbidity observed in this study. Angiogenesis is defined 261 as the de novo formation of new blood vessels. Both cancer and AAA share angiogenesis as a common 262 feature in their pathophysiology(44), with angiogenesis being important for tumour growth and 263 metastasis as well as AAA growth and rupture(45). Since EVAR does not remove the aneurysm sac from the body, it is possible that sac regression may fail to occur after EVAR, as a result of release of 265 pro-angiogenic factors by malignant tissues, with a resultant increased propensity towards endoleaks, 266 sac expansion and even rupture. Other biological pathways that may be affected by concomitant 267 malignancy are those regulating thrombosis and inflammation. The ability of cancer to induce a 268 hypercoagulable state is well known (3) and this may have implications if such a state increases the rate 269 of graft limb occlusions. Additionally, patients with cancer are often prescribed prolonged courses of 270 non-steroidal anti-inflammatory analgesia or steroids for intracranial pressure symptoms, both of which 271 have the potential to influence AAA growth. Inflammation is a key component in AAA 272
pathophysiology. It is therefore important to offer closer follow-up to this patient group following their 273 intervention to treat the AAA. 274
The optimal timing of AAA repair prior to cancer surgery, during or following remains uncertain. 275
Certain malignancies, such as an isolated renal carcinoma, may offer themselves to resection through a 276 retro-peritoneal approach with minimal soiling whilst performing an OAR. However, this may not be 277 the case for a pelvic rectal cancer or a right sided colonic neoplasm. The necessity for bowel resection 278 and possible inoculation of the stent graft material would have the potential for catastrophic post-279 operative consequences. Such patients may benefit from EVAR to treat the AAA and the present meta-280 analysis does suggest that EVAR is a safe technique in this patient group despite a possible hyper-281 coagulable state(3); however, timing of interventions remains an unsolved issue. Further investigation 282 is necessary to define the best-timing for each procedure; meaningful analyses were not possible in our 283 report due to lack of data in the series identified. This may be further investigated in a well-designed 284 prospective observational study. 285
Limitations 286
The principal limitation of this study is the retrospective nature of the articles included in the data 287 synthesis, evidenced by the low star rating (3 or 4 stars for all manuscripts included) that the 288 publications achieved using the Newcastle-Ottawa scale. Individual level patient data were largely not 289 available, apart from the few patients who had an emergency repair, outcomes for which were described 290 in some detail (these were excluded from the meta-analysis to remove bias). Hence, we could not 291 perform meaningful data synthesis regarding timing of aneurysm repair with respect to cancer 292 intervention and therefore the subsequent outcomes. Furthermore, we cannot comment on the risk-293 profile of patients who should be offered AAA repair if they do have a malignancy, given that data 294 regarding the fate of patients managed conservatively is lacking. Another interesting parameter is 295 reporting bias; especially for the EVAR patients, where no deaths were seen within 30 days, there may 296 have been some under-reporting of bad outcomes. Finally, some of the EVAR series in the meta-297 analysis have utilised early generation EVAR devices, which are known to be associated with inferior 298
outcomes. 299
In conclusion early morbidity rates were significant in our meta-analysis but EVAR is superior 300 regarding short-term mortality. A well-designed observational study is required to define the best timing 301 for each procedure in the context of malignancy. 302 303 
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